Description
In recent years, the treatment of microbial multidrug-resistant (MDR) bacterial wound infections (WIs) has faced major challenges worldwide. The utilization of microbial phages and their derived enzymes for the treatment of MDR bacterial WIs has become a hot topic among scholars around the world due to the impotence of conventional antibiotic therapies and the slow development of novel antibiotics. Novel drugs loaded with phages and their derived lysins for the treatment of WIs have received increasing attention compared with conventional phages and their derived enzyme preparations. Therefore, this book summarizes recent advances in the application of novel drugs of microbial phages and their derived enzymes to the treatment of microbial MDR bacterial WIs and points out their advantages and challenges. Thus, this book provides new ideas for the development of a new drug formulation utilizing microbial phages and their derived lysins for the treatment of MDR bacterial WIs, in order to facilitate the early transition from basic research to clinical applications in this field.